US 12,110,491 B2
Selective reduction of allelic variants
C. Frank Bennett, Carlsbad, CA (US); Susan M. Freier, San Diego, CA (US); Sarah Greenlee, San Diego, CA (US); and Eric E. Swayze, Encinitas, CA (US)
Assigned to Ionis Pharmaceuticals, Inc., Carlsbad, CA (US)
Filed by Ionis Pharmaceuticals, Inc., Carlsbad, CA (US)
Filed on Jan. 18, 2022, as Appl. No. 17/577,832.
Application 17/577,832 is a continuation of application No. 15/961,567, filed on Apr. 24, 2018, abandoned.
Application 15/961,567 is a continuation of application No. 14/581,235, filed on Dec. 23, 2014, abandoned.
Application 14/581,235 is a continuation of application No. 13/577,616, granted, now 8,957,040, issued on Feb. 17, 2015, previously published as PCT/US2011/024103, filed on Feb. 8, 2011.
Claims priority of provisional application 61/371,635, filed on Aug. 6, 2010.
Claims priority of provisional application 61/302,469, filed on Feb. 8, 2010.
Prior Publication US 2022/0403386 A1, Dec. 22, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/11 (2006.01); C12N 15/113 (2010.01)
CPC C12N 15/113 (2013.01) [C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/341 (2013.01); C12N 2310/346 (2013.01); C12N 2320/34 (2013.01); C12N 2320/35 (2013.01)] 50 Claims
 
1. A compound comprising a modified oligonucleotide consisting of 20 linked nucleosides and comprising a nucleobase sequence having at least 95% sequence identity to the nucleobase sequence of SEQ ID NO: 274, wherein the modified oligonucleotide comprises at least one nucleoside comprising a modified sugar and at least one modified internucleoside linkage, wherein each T in SEQ ID NO: 274 is independently a T or a U, and wherein the modified oligonucleotide is a gapmer.